Ulcerative Colitis

The results show adherence to 6 quality indicators was linked to improvements in the post-intervention cohort with significant increases in C difficile testing, CRP testing, testing for latent tuberculosis, thromboprophylaxis, adequate corticosteroids prescription, and limitation of narcotics prescribed.

The rate of adverse events was lower in the combination group than it was in patients in the guselkumab or golimumab monotherapy groups at week 50.

The FDA has approved several biologics in recent years for the treatment of patients with inflammatory bowel disease.

There is very little data on long-term outcomes from pediatric patients with inflammatory bowel disease treated with anti-TNF biosimilars.

Risankizumab is the latest biologic approved by the FDA and the first-ever IL-23A targeted therapy approved for the treatment of patients with Crohn's disease.

There is not much data available on the interaction between Paxlovid and tacrolimus.

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

The 12-24 session counseling program also resulted in improvements in sleep quality, fatigue level, and stress levels for patients with inflammatory bowel disease.

The majority of patients who achieved persistence at the 12 month mark were also corticosteroid free.

The product is a combination of herbal compounds curcumin and QingDai called CurQD.

Microscopic inflammation can be an important indicator of disease activity in patients with ulcerative colitis.

There was no differences in serious adverse event rates between patients treated with the combination therapy and patients who withdrew from infliximab or immunosuppressant therapy.

The guidelines include advocating for more preventative care and changing how the disease is diagnosed.

Gut microbiota diversity was lower in below average responders, while 39.5% of participants had a serological response below the geometric mean.

Ulcerative colitis was considered an independent risk factor, while Crohn’s disease and unclassified inflammatory bowel disease were not.

RBX2660 is the first ever live microbiota therapeutic approved by the FDA.

The results show patients with preclinical IBD had an increased in primary care visits up to 3-5 years prior to a diagnosis.

In 2021, the USPSTF changed guidance on colorectal cancer screenings, reducing the recommended age of a colonoscopy from 50 to 45 years.

There was also higher neutralizing antibody titers against BA.4/5 with a lower hazard risk in the group with a breakthrough infection.

Prometheus Biosciences is expected to begin phase 3 trials for the treatment in 2023.

The male gender was positively associated with a higher risk of serious infection at month 12 and penetrating disease behavior was positively associated with 12-month treatment persistence.

David P. Hudesman, MD, discusses clinical implications from ACG 2022 data on ustekinumab therapy for the management of ulcerative colitis and shares advice for managing patients with the disease.

David P. Hudesman, MD, reviews long-term extension study data for the corticosteroid-sparing effects of ustekinumab on ulcerative colitis as presented at ACG 2022.